Advancing access to CNS care: Neuraxpharm’s enduring commitment
We are proud to share an overview of our mission and our dedication to improving the lives of patients affected by neurological and psychiatric disorders.
Watch the video linked here and join us on our journey of innovation, growth and dedication to CNS patients everywhere.
Some highlights of our journey:
- Focus on innovation – investment in new solutions, in the field of multiple sclerosis, with the goal of improving the quality of life of our patients.
- Focus on well-established treatments – investment in market-leading brands, including Buccolam® and recently acquired Provigil® and Nuvigil®.
- International expansion – reaching 98% of the CNS market in Europe through a presence in 50+ countries across Europe and beyond, including 3 affiliates (two in Latin America and one in the Middle East); enabling patients worldwide to benefit from our CNS expertise.
- Transforming lives – a portfolio of over 120 CNS molecules, including 20+ new products in the pipeline; addressing chronic as well as rare and life-threatening conditions with pioneering approaches.
A summary of our recent milestones:
- Acquisition of Provigil® and Nuvigil® to support narcolepsy patients in Europe and beyond, including new territories such as Australia and Mexico.
- A strategic collaboration with Pharmathen to deliver and commercialise long-acting injectables within the psychiatry field, offering patients greater flexibility and control in managing their condition.
- Positive NEXUS trial results for leriglitazone, a potential breakthrough for patients and families facing the challenges of cerebral adrenoleukodystrophy.
Looking forward, we remain dedicated to delivering innovative solutions, strengthening partnerships, and improving access to care for CNS patients in need.
Find out more about our recent news here:Â https://www.neuraxpharm.com/news/